

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

29 Jun 2026

### The effect of calcipotriol ointment in the treatment of cutaneous wart

#### Protocol summary

##### Study aim

The effect of calcitriol ointment on the treatment of skin warts

##### Design

Two arm parallel-group randomised trial with blinded postoperative care and outcome assessment

##### Settings and conduct

This study is a randomized controlled clinical trial and all patients with cutaneous warts referred to dermatology clinic of Bu Ali Sina Hospital in Sari during the years 98 to 99 with inclusion criteria and excluding exclusion criteria were included. Individuals' personal information including age, sex, number of lesions, duration of the lesion is recorded in the questionnaire by the designers.

##### Participants/Inclusion and exclusion criteria

Inclusion criteria: Patients with cutaneous warts that are diagnosed by a dermatologist clinically or pathologically and need treatment. - Over 4 years old - Informed consent to enter the study -The number of warts up to 20  
Exclusion criteria: - Children under 2 years, pregnant and lactating women - Patients who are contraindicated for calcipotriol treatment. - Facial genital warts - Patients who do not consent to participate in the study. - People who are allergic to topical vitamin D derivatives. - Widespread warts that need further treatment.

##### Intervention groups

Intervention group: 0.005% calcitriol ointment in addition to the routine treatment twice daily (every 12 hours) is applied by the patient or his / her parents on the lesions so that the ointment with a thickness of one millimetre is applied on the lesion surface. Control group: Only receive routine treatment.

##### Main outcome variables

Response to treatment is considered complete response, partial improvement (reduction in the number and in individual lesions size reduction) as of measurement and expression of percentage and no improvement, and 4 months after complete recovery of the patient, recurrence of lesions is examined.

#### General information

##### Reason for update

typographical mistakes

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20170818035762N2**

Registration date: **2020-02-17, 1398/11/28**

Registration timing: **registered\_while\_recruiting**

Last update: **2020-09-30, 1399/07/09**

Update count: **1**

##### Registration date

2020-02-17, 1398/11/28

##### Registrant information

###### Name

**Name of organization / entity**

###### Country

Iran (Islamic Republic of)

###### Phone

+98 11 4221 8021

###### Email address

a.kazeminejad@mazums.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2020-01-21, 1398/11/01

##### Expected recruitment end date

2020-03-20, 1399/01/01

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

##### Scientific title

The effect of calcipotriol ointment in the treatment of

cutaneous wart

### Public title

The effect of calcitriol ointment on skin warts

### Purpose

Treatment

### Inclusion/Exclusion criteria

#### Inclusion criteria:

Patients with cutaneous warts that are clinically or pathologically diagnosed by a dermatologist and need treatment The number of warts up to 20 Minimum enrollment age is 4 years

#### Exclusion criteria:

People who are allergic to topical vitamin D derivatives. Warts that need further treatment.

### Age

From **4 years** old

### Gender

Both

### Phase

3

### Groups that have been masked

- Participant
- Care provider
- Investigator
- Data analyser

### Sample size

Target sample size: **56**

### Randomization (investigator's opinion)

Randomized

### Randomization description

First, according to the inclusion criteria, 56 patient will be selected by the available sampling method. Then, this 56 patient will be assigned to 2 intervention and control groups. The blocking process will be done with the Rando allocation software. This software will create 14 blocks containing 4 patient and the samples will be grouped accordingly.

### Blinding (investigator's opinion)

Double blinded

### Blinding description

Blinding in this study will be done like this the intervention group will receive routine treatment in addition to calcitriol ointment and the control group will receive only routine treatment. The researcher, patient, and individual analyzer will not be aware of the type of medication prescribed by the physician.

### Placebo

Used

### Assignment

Parallel

### Other design features

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Ethics committee of Mazandaran University of Medical Sciences

##### Street address

Vice chancellor for research. University Building number2 .Moalem Square.Sari

##### City

sari

##### Province

Mazandaran

##### Postal code

۴۸۱۵۷۳۳۹۷۱

#### Approval date

2020-01-05, 1398/10/15

#### Ethics committee reference number

IR.MAZUMS.REC.1398.1259

## Health conditions studied

### 1

#### Description of health condition studied

Skin warts

#### ICD-10 code

B07

#### ICD-10 code description

Viral warts

## Primary outcomes

### 1

#### Description

Response to treatment is considered complete response, relative improvement (reduction in number and size reduction in individual lesions) as measurement and expression of percentage and no improvement.

#### Timepoint

The patient is examined monthly by a dermatologist

#### Method of measurement

Based on clinical examination of dermatologist

## Secondary outcomes

empty

## Intervention groups

### 1

#### Description

Intervention group: 0.005% calcipotriol ointment in addition to the routine treatment twice daily (every 12 hours) is applied by the patient or his / her parents on the lesions, so that the ointment with a thickness of one millimeter is applied on the lesion surface. . The patient is visited by a physician on a monthly basis the number and size of lesions, complications such as erythema and scaling around the lesion, pain, worsening of the lesions,

and other associated symptoms. Treatment is continued for 2 months and if not treated for up to 4 months.

**Category**

Treatment - Drugs

**2****Description**

Control group: This group will only receive routine treatment

**Category**

Other

**Recruitment centers****1****Recruitment center****Name of recruitment center**

Sari Bou Ali Hospital

**Full name of responsible person**

Dr.Armaghan Kazeminejad

**Street address**

Headquarters of Mazandaran University of Medical Sciences. At the beginning of Valiasr Highway.Jouybar Road.Sari

**City**

Sari

**Province**

Mazandaran

**Postal code**

۳۳۹۷۱۴۸۱۵۷

**Phone**

+98 11 3304 4001

**Email**

publicrel@mazums.ac.ir

**Sponsors / Funding sources****1****Sponsor****Name of organization / entity**

Mazandaran University of Medical Sciences

**Full name of responsible person**

Dr. Majid Saeedi

**Street address**

Headquarters of Mazandaran University of Medical Sciences. At the beginning of Valiasr Highway.Sari

**City**

Sari

**Province**

Mazandaran

**Postal code**

4414733971

**Phone**

+98 11 3304 4001

**Email**

publicrel@mazums.ac.ir

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor****organization/entity?**

No

**Title of funding source**

No

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

*empty*

**Country of origin****Type of organization providing the funding**

Academic

**Person responsible for general inquiries****Contact****Name of organization / entity**

Mazandaran University of Medical Sciences

**Full name of responsible person**

Dr.ArMarghan Kazeminejad

**Position**

Associate professor

**Latest degree**

Specialist

**Other areas of specialty/work**

Dermatology

**Street address**

Headquarters of Mazandaran University of Medical Sciences. At the beginning of Valiasr Highway.Sari

**City**

Sari

**Province**

Mazandaran

**Postal code**

4815733971

**Phone**

+98 11 3304 4001

**Email**

A.kazeminejad@mazums.ac.ir

**Person responsible for scientific inquiries****Contact****Name of organization / entity**

Mazandaran University of Medical Sciences

**Full name of responsible person**

Dr.Armaghan KazemiNejad

**Position**

Associate professor

**Latest degree**

Specialist

**Other areas of specialty/work**

Dermatology

**Street address**

Headquarters of Mazandaran University of Medical Sciences. At the beginning of Valiasr Highway.Sari

**City**

Sari

**Province**

Mazandaran

**Postal code**

4815733971

**Phone**

+98 11 3304 4001

**Email**

A.kazeminejad@mazums.ac.ir

**Person responsible for updating data****Contact****Name of organization / entity**

Mazandaran University of Medical Sciences

**Full name of responsible person**

Dr Armaghan Kazeminejad

**Position**

Associate professor

**Latest degree**

Specialist

**Other areas of specialty/work**

Dermatology

**Street address**

Headquarters of Mazandaran University of Medical Sciences. At the beginning of Valiasr Highway.Sari

**City**

Sari

**Province**

Mazandaran

**Postal code**

4815733971

**Phone**

+98 11 3304 4001

**Email**

A.kazeminejad@mazums.ac.ir

**Sharing plan****Deidentified Individual Participant Data Set (IPD)**

Yes - There is a plan to make this available

**Study Protocol**

Yes - There is a plan to make this available

**Statistical Analysis Plan**

No - There is not a plan to make this available

**Informed Consent Form**

Undecided - It is not yet known if there will be a plan to make this available

**Clinical Study Report**

Yes - There is a plan to make this available

**Analytic Code**

Undecided - It is not yet known if there will be a plan to make this available

**Data Dictionary**

Undecided - It is not yet known if there will be a plan to make this available

**Title and more details about the data/document**

Only part of the data, such as information about the main outcome or the like, can be shared

**When the data will become available and for how long**

Start of access period 6 months after establishing results

**To whom data/document is available**

It will only be available to researchers working in academic and scientific institutions

**Under which criteria data/document could be used**

It will only be available to researchers working in academic and scientific institutions

**From where data/document is obtainable**

Email to: A.kazeminejad@mazums.ac.ir

**What processes are involved for a request to access data/document**

After communicating with the email if available, data and results will be available

**Comments**